The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Category: Clinical & Manufacturing

FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013
Clinical & Manufacturing

FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013

APR 28, 2023
Vedanta Biosciences Publishes Phase 2 Results
Clinical & Manufacturing

Vedanta Biosciences Publishes Phase 2 Results

APR 18, 2023
Microbiotica Announces Clinical Trial Collaboration with MSD
Clinical & Manufacturing

Microbiotica Announces Clinical Trial Collaboration with MSD

APR 13, 2023
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101
Clinical & Manufacturing

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101

JAN 24, 2023
New study reveals DSM’s Fruitflow® activates gut-heart axis that can modulate gut microbiota leading to cardiovascular benefits
Clinical & Manufacturing

New study reveals DSM’s Fruitflow® activates gut-heart axis that can modulate gut microbiota leading to cardiovascular benefits

JAN 24, 2023
NIH-supported clinical trial of phage therapy for cystic fibrosis begins
Clinical & Manufacturing

NIH-supported clinical trial of phage therapy for cystic fibrosis begins

OCT 19, 2022
MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies
Clinical & Manufacturing

MaaT Pharma and Skyepharma Enter Partnership to Establish Manufacturing Facility for Microbiome Ecosystem Therapies

FEB 9, 2022
BioGaia’s probiotic reduces inflammation in patients with diverticulitis
Biotics and Supplements

BioGaia’s probiotic reduces inflammation in patients with diverticulitis

FEB 9, 2022
Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection
Clinical & Manufacturing

Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection

JAN 24, 2022
Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD
Clinical & Manufacturing

Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD

DEC 6, 2021
Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
Clinical & Manufacturing

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

NOV 19, 2021